Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Immunoglobulin Fab Fragments"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 28
Tytuł:
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Autorzy:
Holmes LE; South Western Sydney Clinical School, The University of New South Wales, Sydney, NSW, Australia.; Cardiology Department, Liverpool Hospital, Sydney, NSW, Australia.
Gupta R; South Western Sydney Clinical School, The University of New South Wales, Sydney, NSW, Australia.; Cardiology Department, Liverpool Hospital, Sydney, NSW, Australia.
Rajendran S; South Western Sydney Clinical School, The University of New South Wales, Sydney, NSW, Australia.; Cardiology Department, Liverpool Hospital, Sydney, NSW, Australia.
Luu J; South Western Sydney Clinical School, The University of New South Wales, Sydney, NSW, Australia.; Cardiology Department, Liverpool Hospital, Sydney, NSW, Australia.
French JK; South Western Sydney Clinical School, The University of New South Wales, Sydney, NSW, Australia.; Cardiology Department, Liverpool Hospital, Sydney, NSW, Australia.
Juergens CP; South Western Sydney Clinical School, The University of New South Wales, Sydney, NSW, Australia. .; Cardiology Department, Liverpool Hospital, Sydney, NSW, Australia. .
Pokaż więcej
Źródło:
Cardiovascular therapeutics [Cardiovasc Ther] 2016 Oct; Vol. 34 (5), pp. 330-6.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Percutaneous Coronary Intervention*/adverse effects
Acute Coronary Syndrome/*therapy
Antibodies, Monoclonal/*administration & dosage
Blood Platelets/*drug effects
Immunoglobulin Fab Fragments/*administration & dosage
Peptides/*administration & dosage
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Tyrosine/*analogs & derivatives
Abciximab ; Acute Coronary Syndrome/blood ; Acute Coronary Syndrome/diagnosis ; Adenosine/administration & dosage ; Adenosine/analogs & derivatives ; Aged ; Antibodies, Monoclonal/adverse effects ; Blood Platelets/metabolism ; Clopidogrel ; Drug Therapy, Combination ; Eptifibatide ; Female ; Hemorrhage/chemically induced ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Male ; Middle Aged ; New South Wales ; Peptides/adverse effects ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Function Tests ; Platelet Glycoprotein GPIIb-IIIa Complex/metabolism ; Prasugrel Hydrochloride/administration & dosage ; Purinergic P2Y Receptor Antagonists/administration & dosage ; Receptors, Purinergic P2Y12/blood ; Receptors, Purinergic P2Y12/drug effects ; Risk Factors ; Ticagrelor ; Ticlopidine/administration & dosage ; Ticlopidine/analogs & derivatives ; Time Factors ; Tirofiban ; Treatment Outcome ; Tyrosine/administration & dosage ; Tyrosine/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
Autorzy:
Mazurov AV; Cardiology Research Center, Moscow, Russia. />Pevzner DV
Antonova OA
Byzova TV
Khaspekova SG
Semenov AV
Vlasik TN
Samko AN
Staroverov II
Ruda MY
Pokaż więcej
Źródło:
Platelets [Platelets] 2002 Dec; Vol. 13 (8), pp. 465-77.
Typ publikacji:
Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angioplasty, Balloon, Coronary/*adverse effects
Antibodies, Monoclonal/*therapeutic use
Immunoglobulin Fab Fragments/*therapeutic use
Platelet Aggregation Inhibitors/*pharmacology
Platelet Aggregation Inhibitors/*therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex/*immunology
Abciximab ; Animals ; Antibodies/blood ; Antibodies, Monoclonal/adverse effects ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Immunoglobulin Fab Fragments/metabolism ; Male ; Mice ; Middle Aged ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/pharmacokinetics ; Platelet Count ; Reoperation ; Risk Assessment ; Safety
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Autorzy:
Topol EJ; Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA. />Mark DB
Lincoff AM
Cohen E
Burton J
Kleiman N
Talley D
Sapp S
Booth J
Cabot CF
Anderson KM
Califf RM
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 1999 Dec 11; Vol. 354 (9195), pp. 2019-24.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Angioplasty, Balloon, Coronary*/economics
Stents*/economics
Antibodies, Monoclonal/*administration & dosage
Coronary Disease/*therapy
Immunoglobulin Fab Fragments/*administration & dosage
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Adult ; Aged ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/economics ; Coronary Disease/blood ; Coronary Disease/economics ; Coronary Disease/mortality ; Cost-Benefit Analysis ; Death, Sudden, Cardiac/prevention & control ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Immunoglobulin Fab Fragments/economics ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/economics ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Too much, too little, or none at all: dealing with substandard and fake drugs.
Autorzy:
Wan Po AL; Centre for Evidence-Based Pharmacotherapy, Aston University, Aston Triangle, B4 7ET, Birmingham, UK.
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1904.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Comment
MeSH Terms:
Myocardial Reperfusion*
Thrombolytic Therapy*
Antibodies, Monoclonal/*administration & dosage
Drug and Narcotic Control/*legislation & jurisprudence
Fibrinolytic Agents/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Recombinant Proteins/*administration & dosage
Tissue Plasminogen Activator/*administration & dosage
Abciximab ; Administration, Oral ; Aged ; Antibodies, Monoclonal/adverse effects ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Recombinant Proteins/adverse effects ; Survival Rate ; Tissue Plasminogen Activator/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: Gusto IV-ACS.
Autorzy:
Cohen M; MCP Hahnemann School of Medicine, Division of Cardiology, 19102-1192, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1899-900.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Antibodies, Monoclonal/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Antibodies, Monoclonal/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Myocardial Infarction/mortality ; Randomized Controlled Trials as Topic ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Autorzy:
Topol EJ; Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA.
Pokaż więcej
Corporate Authors:
GUSTO V Investigators
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1905-14.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Myocardial Reperfusion*
Thrombolytic Therapy*
Antibodies, Monoclonal/*administration & dosage
Fibrinolytic Agents/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Recombinant Proteins/*administration & dosage
Tissue Plasminogen Activator/*administration & dosage
Abciximab ; Administration, Oral ; Aged ; Antibodies, Monoclonal/adverse effects ; Aspirin/administration & dosage ; Aspirin/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Recombinant Proteins/adverse effects ; Survival Rate ; Tissue Plasminogen Activator/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Autorzy:
Simoons ML; Thoraxcenter, Room H 560, University Hospital Rotterdam, 3000 CA, Rotterdam, Netherlands.
Pokaż więcej
Corporate Authors:
GUSTO IV-ACS Investigators
Źródło:
Lancet (London, England) [Lancet] 2001 Jun 16; Vol. 357 (9272), pp. 1915-24.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antibodies, Monoclonal/*administration & dosage
Immunoglobulin Fab Fragments/*administration & dosage
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Aged ; Antibodies, Monoclonal/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Infusions, Intravenous ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Survival Rate ; Treatment Outcome ; Troponin I/blood ; Troponin T/blood
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combination therapy of intravenous glycoprotein IIB/IIIA inhibitors and tissue plasminogen activator for acute ischemic stroke.
Autorzy:
Dubey D; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, United State.
Banerjee C
Sawhney A
Sharma A
Alberts MJ
Pokaż więcej
Źródło:
Neurology India [Neurol India] 2014 Nov-Dec; Vol. 62 (6), pp. 631-4.
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Antibodies, Monoclonal/*therapeutic use
Brain Ischemia/*drug therapy
Immunoglobulin Fab Fragments/*therapeutic use
Peptides/*therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Stroke/*drug therapy
Tissue Plasminogen Activator/*therapeutic use
Abciximab ; Administration, Intravenous ; Aged ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Drug Therapy, Combination ; Eptifibatide ; Female ; Humans ; Male ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
Autorzy:
Mukherjee D; Gill Heart Institute, Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536-0200, USA. />Roffi M
Pokaż więcej
Źródło:
Journal of interventional cardiology [J Interv Cardiol] 2008 Apr; Vol. 21 (2), pp. 118-21.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Angioplasty, Balloon, Coronary*
Antibodies, Monoclonal/*therapeutic use
Blood Platelets/*drug effects
Immunoglobulin Fab Fragments/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Acute Coronary Syndrome/drug therapy ; Europe ; Humans ; Myocardial Infarction/drug therapy ; Practice Guidelines as Topic ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Autorzy:
McCollam PL; Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN, USA. mccollam_patrick_ />Foster DA
Riesmeyer JS
Pokaż więcej
Źródło:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2003 Jun 15; Vol. 60 (12), pp. 1251-6.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angioplasty, Balloon, Coronary/*statistics & numerical data
Myocardial Infarction/*drug therapy
Myocardial Infarction/*surgery
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Aged ; Antibodies, Monoclonal/economics ; Antibodies, Monoclonal/therapeutic use ; Case-Control Studies ; Drug Costs/statistics & numerical data ; Eptifibatide ; Female ; Hospital Costs/statistics & numerical data ; Hospital Mortality ; Humans ; Immunoglobulin Fab Fragments/economics ; Immunoglobulin Fab Fragments/therapeutic use ; Length of Stay/statistics & numerical data ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Outcome and Process Assessment, Health Care ; Peptides/economics ; Peptides/therapeutic use ; Platelet Aggregation Inhibitors/economics ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex/economics ; Tirofiban ; Treatment Outcome ; Tyrosine/analogs & derivatives ; Tyrosine/economics ; Tyrosine/therapeutic use ; United States/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.
Autorzy:
Iskandar SB; Division of Cardiology, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee 37604, USA. />Kasasbeh ES
Mechleb BK
Garcia I
Jackson A
Fahrig S
Albalbissi K
Henry PD
Pokaż więcej
Źródło:
Journal of interventional cardiology [J Interv Cardiol] 2006 Aug; Vol. 19 (4), pp. 356-63.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Hemoptysis/*chemically induced
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Pulmonary Alveoli/*drug effects
Abciximab ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Eptifibatide ; Female ; Hemoptysis/epidemiology ; Humans ; Immunoglobulin Fab Fragments/adverse effects ; Male ; Middle Aged ; Myocardial Infarction/drug therapy ; Peptides/adverse effects ; Platelet Aggregation Inhibitors/adverse effects ; Pulmonary Alveoli/physiopathology ; Retrospective Studies ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Autorzy:
Judge HM; Cardiovascular Research Unit, Clinical Sciences Centre, Northern General Hospital, Sheffield S5 7AU, UK. />Buckland RJ
Holgate CE
Storey RF
Pokaż więcej
Źródło:
Platelets [Platelets] 2005 Nov; Vol. 16 (7), pp. 398-407.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Blood Platelets*/drug effects
Blood Platelets*/metabolism
Purinergic P2 Receptor Antagonists*
CD40 Ligand/*metabolism
Membrane Proteins/*antagonists & inhibitors
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*pharmacology
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Secretory Vesicles/*metabolism
Abciximab ; Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/pharmacology ; Antibodies, Monoclonal/pharmacology ; Aspirin/pharmacology ; Coagulants/pharmacology ; Humans ; Immunoglobulin Fab Fragments/pharmacology ; Membrane Proteins/metabolism ; Plasminogen Activator Inhibitor 1/metabolism ; Platelet Aggregation/physiology ; Platelet Glycoprotein GPIIb-IIIa Complex/metabolism ; Receptors, Purinergic P2/metabolism ; Receptors, Purinergic P2Y12 ; Receptors, Thrombin/metabolism ; Tirofiban ; Tyrosine/analogs & derivatives ; Tyrosine/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
Autorzy:
Naimushin YA; Institute of Experimental Cardiology, Russian Cardiology Research and Production Complex, Russian Ministry of Health, Moscow, 121552, Russia.
Mazurov AV
Pokaż więcej
Źródło:
Biochemistry. Biokhimiia [Biochemistry (Mosc)] 2005 Jul; Vol. 70 (7), pp. 782-9.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*pharmacology
Platelet Aggregation/*drug effects
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Antibodies, Monoclonal/chemistry ; Calcium/pharmacology ; Fibrinogen/antagonists & inhibitors ; Fibrinogen/chemistry ; Fibrinogen/pharmacology ; Humans ; Immunoglobulin Fab Fragments/pharmacology ; Ligands ; Platelet Activation/drug effects ; Platelet Activation/physiology ; Platelet Aggregation/physiology ; Platelet Glycoprotein GPIIb-IIIa Complex/chemistry ; Platelet Glycoprotein GPIIb-IIIa Complex/physiology ; Platelet Glycoprotein GPIb-IX Complex/antagonists & inhibitors ; Platelet Glycoprotein GPIb-IX Complex/chemistry ; Platelet Glycoprotein GPIb-IX Complex/physiology ; Serotonin/metabolism ; Time Factors ; Tirofiban ; Tyrosine/analogs & derivatives ; Tyrosine/pharmacology ; von Willebrand Factor/antagonists & inhibitors ; von Willebrand Factor/chemistry ; von Willebrand Factor/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Autorzy:
Silva MA; Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA. />Gandhi PJ
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2004 Dec; Vol. 29 (6), pp. 497-510.
Typ publikacji:
Comparative Study; Journal Article; Review
MeSH Terms:
Angina, Unstable/*drug therapy
Diabetes Mellitus/*drug therapy
Myocardial Infarction/*drug therapy
Platelet Aggregation Inhibitors/*pharmacokinetics
Platelet Aggregation Inhibitors/*therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Tyrosine/*analogs & derivatives
Abciximab ; Angina, Unstable/complications ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; Clinical Trials as Topic ; Diabetes Complications ; Eptifibatide ; Humans ; Immunoglobulin Fab Fragments/therapeutic use ; Myocardial Infarction/complications ; Peptides/pharmacokinetics ; Peptides/therapeutic use ; Tirofiban ; Tyrosine/pharmacokinetics ; Tyrosine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Glycoprotein IIB/IIIA-inhibition and microcirculatory alterations during experimental endotoxemia--an intravital microscopic study in the rat.
Autorzy:
Walther A; Department of Anesthesiology, University of Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany. Andreas_ />Czabanka M
Gebhard MM
Martin E
Pokaż więcej
Źródło:
Microcirculation (New York, N.Y. : 1994) [Microcirculation] 2004 Jan-Feb; Vol. 11 (1), pp. 79-88.
Typ publikacji:
Journal Article
MeSH Terms:
Endotoxemia/*blood
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Animals ; Antibodies, Monoclonal/pharmacology ; Cell Adhesion ; Cell Communication ; Endothelium, Vascular/drug effects ; Endothelium, Vascular/pathology ; Endotoxemia/drug therapy ; Endotoxemia/pathology ; Immunoglobulin Fab Fragments/pharmacology ; Leukocytes/physiology ; Male ; Microcirculation/drug effects ; Microcirculation/pathology ; Microscopy, Video ; Permeability/drug effects ; Rats ; Rats, Wistar ; Venules/drug effects ; Venules/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
Autorzy:
Racine E; Intern Med/CNS Business Unit, Sanofi-Synthelabo US, 90 Park Avenue, New York, NY 10016, USA.
Pokaż więcej
Źródło:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2002 Nov 01; Vol. 59 (21 Suppl 7), pp. S27-36.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Antibodies, Monoclonal/*therapeutic use
Immunoglobulin Fab Fragments/*therapeutic use
Myocardial Infarction/*drug therapy
Peptides/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Clinical Trials as Topic ; Drug Therapy, Combination ; Eptifibatide ; Humans ; Myocardial Infarction/diagnosis ; Myocardial Infarction/physiopathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Treatment of acute myocardial infarct with ST segment elevation with a combination of fibrinolytic therapy and abciximab].
Autorzy:
Gligić B; Vojnomedicinska akademija, Klinika za urgentnu internu medicinu, Beograd.
Dincić D
Obradović S
Marković M
Orozović V
Pokaż więcej
Transliterated Title:
Primena kombinacije fibrinoliticke terapije i abciksimaba u lecenju akutnog infarkta srca sa elevacijom ST segmenta.
Źródło:
Vojnosanitetski pregled [Vojnosanit Pregl] 2002 Nov-Dec; Vol. 59 (6), pp. 675-80.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Thrombolytic Therapy*
Antibodies, Monoclonal/*therapeutic use
Immunoglobulin Fab Fragments/*therapeutic use
Myocardial Infarction/*drug therapy
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
Abciximab ; Adult ; Electrocardiography ; Fibrinolytic Agents/therapeutic use ; Humans ; Male ; Myocardial Infarction/physiopathology ; Tissue Plasminogen Activator/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 28

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies